Thanks Janice for telling me about this new trial!
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
This randomized phase II trial studies the effects of erismodegib (LDE225) on disseminated tumor cells (DTCs) in patients with stage III-III estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The presence of DTCs after completing treatment for breast cancer may be linked to recurrence of the disease. LDE225 may eliminate DTCs in bone marrow and reduce the risk of recurrence.
My breast oncologist at Washington University is working on this clinical trial: LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer. I was not a candidate for trial because I had recurrence and one of prereqs is no recurrence incidents. From a lay person's understanding the way she explained it to me was like this:
1. This clinical trial thinks cancer cells might hide out in bone marrow that most non-lethal chemo regimens cannot kill because most chemo administered is not at the lethal levels that kills cells in the bone marrow itself (note: I'm not a doctor so don't hold me to this but I think if you get bone marrow &/or stem cell transplant they set out to kill all cells even cells in bone marrow and then they reseed your cells from scratch somehow in the bone marrow)
2. This trial will take a sample of your bone marrow to evaluate Disseminating Tumor Cell (DTC) presence, then treat you in such a way to train your immunity system to see the DTCs as some sort of allergy with the hope your immunity system will attack/rid your bone marrow of the DTCs. After x-months they take another sample of your bone marrow to evaluate DTC
Thanks for explaining about this trial in more detail. It sounds very encouraging and hope to see good results. Five or six years ago, there was much discussion about bisphosphonates and whether they could help prevent a recurrence. Maybe it had more to do with the bone marrow and cancer cells.
Donna
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09) 11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15
Personalized Vaccine Therapy in Treating Patients with Triple-Negative Breast Cancer
Basic Trial Information
Phase
Type
Age
Trial IDs
Phase I
Biomarker/Laboratory analysis, Treatment
18 and over
201506113 NCI-2015-01050, NCT02427581
Trial Description
Summary
TRIAL STATUS: Active
This phase I trial studies the side effects and best dose of personalized synthetic long peptide vaccine therapy in treating patients with triple-negative breast cancer. A peptide is a naturally occurring biological molecule made up of amino acids. The personalized synthetic long peptide vaccine is designed to target mutations (any change in the deoxyribonucleic acid [DNA] sequence of a cell) specific to each person’s tumor that are discovered during genetic testing of the tumor before study procedures start. Injection of this vaccine may be a way to generate an immune response to breast cancer cells.
Clinical Trials for TNBC in 2021. You can click on the link and narrow your search by clinical trial phase, region, state, facility, etc. Currently, there are over 172 clinical trials listed for TNBC in the U.S.
I am a BRCA1+ grandson, son and father of women affected by breast/oc-my daughter inherited mutation from me, and at 36, was dx 2004 TNBC I am a volunteer patient advocate with SAGE Patient Advocates
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum